Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2026)
Aytu Biopharma (AYTU) reported Gains from Sales and Divestitures of $83907.0 for Q1 2026, up 776.13% year-over-year from $9577.0 in Q1 2025, and up 3.44% quarter-over-quarter from $81119.0 in Q4 2025.
Aytu Biopharma (AYTU) Gains from Sales and Divestitures (2018 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 9 years of Gains from Sales and Divestitures data on file, last reported at $83907.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $83907.0, up 776.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $83907.0 (up 776.13% YoY), and the FY2025 annual result was $11193.0, up 397.69% from the prior year.
- Gains from Sales and Divestitures rose to $83907.0 in Q1 2026 per AYTU's latest filing, from $81119.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $112787.0 in Q1 2022 and troughed at $333.0 in Q4 2022.
- A 5-year average of $23392.6 and a median of $9577.0 in 2025 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures surged 3560.36% in 2023, then tumbled 95.4% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $333.0 in 2022, then surged by 3560.36% to $12189.0 in 2023, then tumbled by 35.57% to $7853.0 in 2024, then soared by 932.97% to $81119.0 in 2025, then rose by 3.44% to $83907.0 in 2026.
- Business Quant data shows AYTU's Gains from Sales and Divestitures at $83907.0 in Q1 2026, $81119.0 in Q4 2025, and $1618.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Aytu Biopharma | 23.76 Mn | -2.96 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,907.00 |
| Mar 31, 2026 | 83,907.00 |
| Dec 31, 2025 | 81,119.00 |
| Dec 31, 2025 | 81,119.00 |
| Sep 30, 2025 | 1,618.00 |
| Sep 30, 2025 | 1,618.00 |
| Jun 30, 2025 | 11,193.00 |
| Jun 30, 2025 | 11,193.00 |
| Mar 31, 2025 | 9,577.00 |
| Mar 31, 2025 | 9,577.00 |
| Dec 31, 2024 | 7,853.00 |
| Dec 31, 2024 | 7,853.00 |
| Sep 30, 2024 | 564.00 |
| Sep 30, 2024 | 564.00 |
| Jun 30, 2024 | 2,249.00 |
| Jun 30, 2024 | 2,249.00 |
| Mar 31, 2024 | 1,688.00 |
| Mar 31, 2024 | 1,688.00 |
| Dec 31, 2023 | 12,189.00 |
| Dec 31, 2023 | 12,189.00 |